Moaddel, Ruin

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 1,609

SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function

Price, N. L., Gomes, A. P., Ling, A. J. Y., Duarte, F. V., Martin-Montalvo, A., North, B. J., Agarwal, B., Ye, L., Ramadori, G., Teodoro, J. S., et al. (2012) · Cell Metabolism

Sirtuins and Resveratrol in MedicineAdipose Tissue and Metabolism

Cited by 1,602

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms

Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 1,260

Plasma proteomic signature of age in healthy humans

Tanaka, T., Biancotto, A., Moaddel, R., Moore, A. Z., Gonzalez‐Freire, M., Aon, M. A., Candia, J., Zhang, P., Cheung, F., Fantoni, G., et al. (2018) · Aging Cell

GDF15 and Related BiomarkersGenetics, Aging, and Longevity in Model Organisms

Cited by 562

A high-fat diet and NAD(+) activate Sirt1 to rescue premature aging in Cockayne syndrome

Scheibye-Knudsen, M., Mitchell, S. J., Fang, E. F., Iyama, T., Ward, T., Wang, J., Dunn, C. A., Singh, N., Veith, S., Hasan-Olive, M. M., et al. (2014) · Cell Metabolism

Sirtuins and Resveratrol in MedicineGenetics, Aging, and Longevity in Model Organisms

Cited by 352

Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study

Ibrahim, L., DiazGranados, N., Franco-Chaves, J., Brutsche, N., Henter, I. D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D. A., Manji, H. K., et al. (2012) · Neuropsychopharmacology

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 309

Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression

Zarate, C. A., Brutsche, N., Laje, G., Luckenbaugh, D. A., Venkata, S. L. V., Ramamoorthy, A., Moaddel, R., & Wainer, I. W. (2012) · Biological Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 282

Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects

Nugent, A. C., Ballard, E. D., Gould, T. D., Park, L. T., Moaddel, R., Brutsche, N. E., & Zarate, C. A. (2019) · Molecular Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 250

Sub-anesthetic concentrations of (R, S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors

Moaddel, R., Abdrakhmanova, G., Kozak, J., Jozwiak, K., Toll, L., Jimenez, L., Rosenberg, A., Tran, T., Xiao, Y., Zarate, C. A., et al. (2013) · European Journal of Pharmacology

Nicotinic Acetylcholine Receptors StudyNeuroscience and Neuropharmacology Research

Cited by 176

Antidepressant-relevant concentrations of the ketamine metabolite (2 R ,6 R )-hydroxynorketamine do not block NMDA receptor function

Lumsden, E. W., Troppoli, T. A., Myers, S. J., Zanos, P., Aracava, Y., Kehr, J., Lovett, J., Kim, S., Wang, F.-H., Schmidt, S., et al. (2019) · Proceedings of the National Academy of Sciences

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 158

( 2R,6R )-hydroxynorketamine exerts mGlu 2 receptor-dependent antidepressant actions

Zanos, P., Highland, J. N., Stewart, B. W., Georgiou, P., Jenne, C. E., Lovett, J., Morris, P. J., Thomas, C. J., Moaddel, R., Zarate, C. A., et al. (2019) · Proceedings of the National Academy of Sciences

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 152

Proteomics in aging research: A roadmap to clinical, translational research

Moaddel, R., Ubaida‐Mohien, C., Tanaka, T., Lyashkov, A., Basisty, N., Schilling, B., Semba, R. D., Franceschi, C., Gorospe, M., & Ferrucci, L. (2021) · Aging Cell

Genetics, Aging, and Longevity in Model OrganismsAdvanced Proteomics Techniques and Applications

Cited by 139

Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression

Zhao, X., Venkata, S. L. V., Moaddel, R., Luckenbaugh, D. A., Brutsche, N. E., Ibrahim, L., Zarate Jr, C. A., Mager, D. E., & Wainer, I. W. (2012) · British Journal of Clinical Pharmacology

Treatment of Major DepressionPharmacogenetics and Drug Metabolism

Cited by 137

(R,S)-Ketamine Metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine Increase the Mammalian Target of Rapamycin Function

Paul, R. K., Singh, N. S., Khadeer, M., Moaddel, R., Sanghvi, M., Green, C. E., O’Loughlin, K., Torjman, M. C., Bernier, M., & Wainer, I. W. (2014) · Anesthesiology

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 115

Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters

Can, A., Zanos, P., Moaddel, R., Kang, H. J., Dossou, K. S. S., Wainer, I. W., Cheer, J. F., Frost, D. O., Huang, X.-P., & Gould, T. D. (2016) · The Journal of Pharmacology and Experimental Therapeutics

Treatment of Major DepressionNeurotransmitter Receptor Influence on Behavior

Cited by 115

Stereoselective and regiospecific hydroxylation of ketamine and norketamine

Desta, Z., Moaddel, R., Ogburn, E. T., Xu, C., Ramamoorthy, A., Venkata, S. L. V., Sanghvi, M., Goldberg, M. E., Torjman, M. C., & Wainer, I. W. (2012) · Xenobiotica

Pharmacogenetics and Drug MetabolismForensic Toxicology and Drug Analysis

Cited by 114

A parallel chiral-achiral liquid chromatographic method for the determination of the stereoisomers of ketamine and ketamine metabolites in the plasma and urine of patients with complex regional pain syndrome

Moaddel, R., Venkata, S. L. V., Tanga, M. J., Bupp, J. E., Green, C. E., Iyer, L., Furimsky, A., Goldberg, M. E., Torjman, M. C., & Wainer, I. W. (2010) · Talanta

Analytical Chemistry and ChromatographyAnalytical Methods in Pharmaceuticals

Cited by 108

Plasma Biomarkers of Poor Muscle Quality in Older Men and Women from the Baltimore Longitudinal Study of Aging

Moaddel, R., Fabbri, E., Khadeer, M. A., Carlson, O. D., Gonzalez-Freire, M., Zhang, P., Semba, R. D., & Ferrucci, L. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences

Nutrition and Health in AgingMuscle metabolism and nutrition

Cited by 99

Elevated Plasma Growth and Differentiation Factor 15 Is Associated With Slower Gait Speed and Lower Physical Performance in Healthy Community-Dwelling Adults

Semba, R. D., Gonzalez-Freire, M., Tanaka, T., Biancotto, A., Zhang, P., Shardell, M., Moaddel, R., CHI Consortium, & Ferrucci, L. (2020) · The Journals of Gerontology Series A

GDF15 and Related BiomarkersNutrition and Health in Aging

Cited by 94

Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications

Highland, J. N., Zanos, P., Riggs, L. M., Georgiou, P., Clark, S. M., Morris, P. J., Moaddel, R., Thomas, C. J., Zarate, C. A., Pereira, E. F. R., et al. (2021) · Pharmacological Reviews

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 92

D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression

Moaddel, R., Luckenbaugh, D. A., Xie, Y., Villaseñor, A., Brutsche, N. E., Machado-Vieira, R., Ramamoorthy, A., Lorenzo, M. P., Garcia, A., Bernier, M., et al. (2015) · Psychopharmacology

Treatment of Major DepressionTryptophan and brain disorders

Cited by 86

Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression

Farmer, C. A., Gilbert, J. R., Moaddel, R., George, J., Adeojo, L., Lovett, J., Nugent, A. C., Kadriu, B., Yuan, P., Gould, T. D., et al. (2020) · Neuropsychopharmacology

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 85

Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites

Morris, P. J., Moaddel, R., Zanos, P., Moore, C. E., Gould, T., Zarate, C. A., & Thomas, C. J. (2017) · Organic Letters

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 83

(R)‐Ketamine exerts antidepressant actions partly via conversion to (2R,6R)‐hydroxynorketamine, while causing adverse effects at sub‐anaesthetic doses

Zanos, P., Highland, J. N., Liu, X., Troppoli, T. A., Georgiou, P., Lovett, J., Morris, P. J., Stewart, B. W., Thomas, C. J., Thompson, S. M., et al. (2019) · British Journal of Pharmacology

Treatment of Major DepressionTryptophan and brain disorders

Cited by 82